Clarence Eng

425 total citations
16 papers, 342 citations indexed

About

Clarence Eng is a scholar working on Genetics, Cancer Research and Molecular Biology. According to data from OpenAlex, Clarence Eng has authored 16 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 6 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in Clarence Eng's work include Chronic Lymphocytic Leukemia Research (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Fibroblast Growth Factor Research (3 papers). Clarence Eng is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Fibroblast Growth Factor Research (3 papers). Clarence Eng collaborates with scholars based in United States, Canada and United Kingdom. Clarence Eng's co-authors include Mitesh J. Borad, Nathan Bahary, Salvatore A. Del Prete, Joe Stephenson, Brian Ulrich, Allen Lee Cohn, Peter J. Rosen, Stew Kroll, Mark U. Rarick and Tomislav Dragovich and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Human Pathology.

In The Last Decade

Clarence Eng

16 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Clarence Eng United States 8 158 131 130 79 55 16 342
Bérengère Dadone France 11 102 0.6× 178 1.4× 120 0.9× 172 2.2× 64 1.2× 17 377
Qing-Qing Cai China 11 196 1.2× 196 1.5× 162 1.2× 54 0.7× 102 1.9× 15 439
Yuji Shimoda Japan 10 229 1.4× 133 1.0× 210 1.6× 132 1.7× 99 1.8× 26 410
Ningning Dong China 11 142 0.9× 194 1.5× 178 1.4× 93 1.2× 36 0.7× 20 479
Nadina Erill Spain 11 89 0.6× 155 1.2× 166 1.3× 52 0.7× 61 1.1× 16 450
Ji Shin Lee South Korea 11 93 0.6× 185 1.4× 81 0.6× 114 1.4× 59 1.1× 13 334
Gian Luca Rampioni Vinciguerra Italy 12 107 0.7× 238 1.8× 181 1.4× 134 1.7× 41 0.7× 26 452
Sui Peng China 11 129 0.8× 114 0.9× 91 0.7× 83 1.1× 44 0.8× 24 402
Mogens K. Boisen Denmark 13 154 1.0× 151 1.2× 261 2.0× 79 1.0× 59 1.1× 23 443
Daniela Bianconi Austria 10 74 0.5× 100 0.8× 161 1.2× 64 0.8× 21 0.4× 23 306

Countries citing papers authored by Clarence Eng

Since Specialization
Citations

This map shows the geographic impact of Clarence Eng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clarence Eng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clarence Eng more than expected).

Fields of papers citing papers by Clarence Eng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clarence Eng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clarence Eng. The network helps show where Clarence Eng may publish in the future.

Co-authorship network of co-authors of Clarence Eng

This figure shows the co-authorship network connecting the top 25 collaborators of Clarence Eng. A scholar is included among the top collaborators of Clarence Eng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clarence Eng. Clarence Eng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Wang, Yujin, Daria B. Crittenden, Clarence Eng, et al.. (2021). Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver‐Distributed Farnesoid X‐Receptor Agonist TERN‐101 in Healthy Volunteers. Clinical Pharmacology in Drug Development. 10(10). 1198–1208. 18 indexed citations
2.
Catenacci, Daniel V.T., Anteneh Tesfaye, Eric Cheung, et al.. (2019). Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design. Future Oncology. 15(18). 2073–2082. 56 indexed citations
3.
Tejani, Mohamedtaki Abdulaziz, Eric Cheung, Peter D. Eisenberg, et al.. (2019). Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).. Journal of Clinical Oncology. 37(4_suppl). 91–91. 8 indexed citations
4.
5.
Sharman, Jeff P., Andrei R. Shustov, Mitchell R. Smith, et al.. (2015). Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling. Blood. 126(23). 1744–1744. 3 indexed citations
6.
Sharman, Jeff P., Leonard M. Klein, Michael Boxer, et al.. (2015). Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL). Blood. 126(23). 1545–1545. 12 indexed citations
7.
8.
Sharman, Jeff P., Leonard M. Klein, Michael Boxer, et al.. (2015). Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood. 126(23). 4152–4152. 3 indexed citations
9.
Brenner, Andrew, Jessica D. Sun, John Floyd, et al.. (2014). Phase 1/2 study of investigational hypoxia-targeted drug, TH-302, and bevacizumab (bev) in recurrent glioblastoma (GBM) following bev failure.. Journal of Clinical Oncology. 32(15_suppl). 2029–2029. 1 indexed citations
10.
Borad, Mitesh J., Shantan Reddy, Nathan Bahary, et al.. (2014). Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology. 33(13). 1475–1481. 147 indexed citations
11.
Ryan, David P., Shantan Reddy, Nathan Bahary, et al.. (2013). TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC).. Journal of Clinical Oncology. 31(4_suppl). 325–325. 7 indexed citations
12.
Hart, Charles P., Andrew J. Armstrong, E. Gabriela Chiorean, et al.. (2009). Abstract B185: Bench to bedside experience with TH-302: A tumor-selective hypoxia-activated prodrug as a promising treatment for prostate cancer. Molecular Cancer Therapeutics. 8(12_Supplement). B185–B185. 2 indexed citations
13.
Tidmarsh, George F., Laura I. Tanner, Julie O’Connor, Clarence Eng, & Kasia Mordec. (2004). Effect of 2-Deoxyglucose, a Glycolytic Inhibitor, on the ATP Levels and Viability of B Lymphocytes from Subjects with Chronic Lymphocytic Leukemia (CLL).. Blood. 104(11). 4810–4810. 2 indexed citations
14.
Thor, Ann D., Clarence Eng, Sandy DeVries, et al.. (2002). Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Human Pathology. 33(6). 628–631. 64 indexed citations
15.
Moore, Lee E., John K. Wiencke, Clarence Eng, Shichun Zheng, & Allan H. Smith. (2001). Evaluation of buccal cell collection protocols for genetic susceptibility studies. Biomarkers. 6(6). 448–454. 12 indexed citations
16.
Ström, C., et al.. (1985). 863 DETECTION OF GENE DELETIONS IN THE HUMAN TYPE II PROCOLLAGEN GENE IN 8 PATIENTS WITH ACHONDROPLASIA USING GENE DOSAGE ANALYSIS. Pediatric Research. 19(4). 254A–254A. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bérengère Dadone Breakdown of academic impact, for papers by Qing-Qing Cai Breakdown of academic impact, for papers by Yuji Shimoda Breakdown of academic impact, for papers by Ningning Dong Breakdown of academic impact, for papers by Nadina Erill Breakdown of academic impact, for papers by Ji Shin Lee Breakdown of academic impact, for papers by Gian Luca Rampioni Vinciguerra Breakdown of academic impact, for papers by Sui Peng Breakdown of academic impact, for papers by Mogens K. Boisen Breakdown of academic impact, for papers by Daniela Bianconi
Rankless by CCL
2026